Related Experiment Video
Updated: Jul 12, 2026
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
Published on: January 7, 2019
Pathology and clinical course of MALT lymphoma with plasmacytic differentiation
S Wöhrer1, M Troch, B Streubel
1Department of Internal Medicine I, Medical University of Vienna, Austria.
Background:
The feature of plasmacytic differentiation (PCD) is present in up to 30% of patients diagnosed with mucosa-associated lymphoid tissue (MALT) lymphoma. To date, the influence of PCD on the clinical course of MALT lymphoma has not been assessed.
Patients And Methods:
Therefore, we have retrospectively analysed the clinical characteristics and the course of the disease in 34 (25%) patients with PCD as compared with 101 (75%) MALT lymphoma patients without this histological feature.
Results:
Patients with PCD had significantly more extragastric lymphomas [28 of 34 (82%) versus 54 of 101 (53%), P = 0.003] and a significantly lower rate of t(11;18) [2 of 26 (8%) versus 22 of 72 (31%), P = 0.02]. There was no significant difference of age at diagnosis (62 versus 64 years, P = 0.64), relapse rate (48% versus 37%, P = 0.27), estimated median time to progression (43 versus 65 months, P = 0.14), monoclonal gammopathy (50% versus 44%, P = 0.63), t(14;18) involving IGH/MALT 1 (11% versus 8%, P = 0.68), trisomy 3 (31% versus 27%, P = 0.69), trisomy 18 (8% versus 10%, P = 0.74) and the presence of autoimmune diseases between both groups (53% versus 37%, P = 0.09).
Conclusion:
In conclusion, we found that PCD is predominantly found in extragastric MALT lymphoma but has no significant impact on clinical course and prognosis.
Insights
Plasmacytic differentiation (PCD) is common in extragastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, this study found PCD does not significantly impact MALT lymphoma
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Mucosa-associated lymphoid tissue (MALT) lymphoma is a type of non-Hodgkin lymphoma.
- Plasmacytic differentiation (PCD) occurs in up to 30% of MALT lymphoma cases.
- The clinical impact of PCD on MALT lymphoma progression remains unassessed.
Purpose of the Study:
- To evaluate the clinical characteristics and disease course of MALT lymphoma patients with PCD.
- To compare outcomes between MALT lymphoma patients with and without PCD.
Main Methods:
- Retrospective analysis of 135 MALT lymphoma patients.
- Comparison of 34 patients with PCD against 101 patients without PCD.
- Assessment of clinical features, disease progression, and prognostic factors.
Main Results:
- PCD was significantly associated with extragastric MALT lymphomas (82% vs 53%, P=0.003).
- Patients with PCD showed a lower rate of t(11;18) translocation (8% vs 31%, P=0.02).
- No significant differences were observed in age, relapse rate, time to progression, or other genetic markers.
Conclusions:
- PCD is predominantly observed in extragastric MALT lymphoma.
- PCD does not appear to significantly influence the clinical course or prognosis of MALT lymphoma.
